Higher age, number of previous treatment lines, number of bone metastases, ECOG-PS score, tALP, PSA, as well as the presence of lymphadenopathies at the time of enrollment, were independently associated with an increased risk of death. This evidence concerns the gene KLK3 and Lymphadenopathy.